| First Author | Kiripolsky J | Year | 2021 |
| Journal | J Autoimmun | Volume | 118 |
| Pages | 102608 | PubMed ID | 33596533 |
| Mgi Jnum | J:327022 | Mgi Id | MGI:6877278 |
| Doi | 10.1016/j.jaut.2021.102608 | Citation | Kiripolsky J, et al. (2021) Tissue-specific activation of Myd88-dependent pathways governs disease severity in primary Sjogren's syndrome. J Autoimmun 118:102608 |
| abstractText | Myd88 activation is an important driver of autoimmunity. Primary Sjogren's syndrome (pSS) is an autoimmune disease characterized by exocrine gland dysfunction in combination with serious systemic disease manifestations. Myd88-dependent signaling networks remain incompletely understood in the context of pSS. The objective of this study was to establish the contribution of tissue-specific Myd88 activation to local (exocrine) and systemic pSS manifestations. To this end, we generated two novel conditional knockout pSS mouse models; one lacking Myd88 in hematopoietic cells and a second strain in which Myd88 was deleted in the stromal compartment. Spontaneous production of inflammatory mediators was altered in salivary tissue, and nephritis was diminished in both conditional knockout strains. In contrast, pulmonary inflammation was increased in mice lacking Myd88 in hematopoietic cells and was reduced when Myd88 was ablated in stromal cells. Finally, anti-nuclear autoantibodies (ANAs) were attenuated in pSS mice lacking Myd88 in immune cells. Additionally, the ANA-specific B cell repertoire was skewed in the Myd88-deficient strains. Collectively, these data demonstrate that Myd88 activation in specific cell types is essential for distinct aspects of pSS pathology. |
